NIAID said early Tuesday it's "concerned" that AstraZeneca "may have included outdated information" from a trial of its COVID-19 vaccine that "may have provided an incomplete view of the efficacy data.

Why it matters: The National Institute of Allergy and Infectious Diseases statement comes after the company announced the vaccine it developed with the University of Oxford was found to be 79% effective at preventing symptomatic COVID-19 and 100% effective against severe disease and hospitalization in a Phase III trial.

• The institute added it's urging AstraZeneca to work with its monitoring board "to review the efficacy data and ensure the most accurate, up-to-date efficacy data be made public as quickly as possible."

Editor's note: This a breaking news story. Please check back for updates.